Pharmacokinetics and pharmacodynamics of intravenous medetomidine in the horse

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective To describe the pharmacodynamics and pharmacokinetics following an intravenous (IV) bolus dose of medetomidine in the horse. Study design Prospective experimental trial. Animals Eight, mature healthy horses age 11.7±4.6 (mean±SD) years, weighing 557±54kg. Methods Medetomidine (10μgkg -1) was administered IV. Blood was sampled at fixed time points from before drug administration to 48hours post administration. Behavioral, physiological and biochemical data were obtained at predetermined time points from 0minutes to 24hours post administration. An algometer was also used to measure threshold responses to noxious stimuli. Medetomidine concentrations were determined by liquid chromatography-Mass Spectrometry and used for calculation of pharmacokinetic parameters using noncompartmental and compartmental analysis. Results Pharmacokinetic analysis estimated that medetomidine peaked (8.86±3.87ngmL -1) at 6.4±2.7minutes following administration and was last detected at 165±77minutes post administration. Medetomidine had a clearance of 39.6±14.6mLkg -1minute -1 and a volume of distribution of 1854±565mLkg -1. The elimination half-life was 29.1±12.5minutes. Glucose concentration reached a maximum of 176±46mgdL -1 approximately 1hour post administration. Decreased heart rate, respiratory rate, borborygmi, packed cell volume, and total protein concentration were observed following administration. Horses lowered their heads from 107±12 to 20±10cm within 10minutes of drug administration and gradually returned to normal. Horse mobility decreased after drug administration. An increased mechanical threshold was present from 10 to 45minutes and horses were less responsive to sound. Conclusion and clinical relevance Behavioral and physiological effects following intravenous administration positively correlate with pharmacokinetic profiles from plasma medetomidine concentrations. Glucose concentration gradually transiently increased following medetomidine administration. The analgesic effect of the drug appeared to have a very short duration.

Original languageEnglish (US)
Pages (from-to)38-48
Number of pages11
JournalVeterinary Anaesthesia and Analgesia
Volume39
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Medetomidine
medetomidine
pharmacology
pharmacokinetics
Horses
Pharmacokinetics
horses
drugs
Pharmaceutical Preparations
Glucose
glucose
analgesic effect
Respiratory Rate
respiratory rate
Cell Size
intravenous injection
Liquid Chromatography
Intravenous Administration
liquid chromatography
half life

Keywords

  • Alpha -adrenergic agonist
  • Horse
  • Medetomidine
  • Pharmacodynamics
  • Pharmacokinetics
  • Sedation

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics and pharmacodynamics of intravenous medetomidine in the horse. / Grimsrud, Kristin N; Mama, Khursheed R.; Steffey, Eugene; Stanley, Scott D.

In: Veterinary Anaesthesia and Analgesia, Vol. 39, No. 1, 01.2012, p. 38-48.

Research output: Contribution to journalArticle

@article{8cbeb1c6056048a4afde5aa235c9afb1,
title = "Pharmacokinetics and pharmacodynamics of intravenous medetomidine in the horse",
abstract = "Objective To describe the pharmacodynamics and pharmacokinetics following an intravenous (IV) bolus dose of medetomidine in the horse. Study design Prospective experimental trial. Animals Eight, mature healthy horses age 11.7±4.6 (mean±SD) years, weighing 557±54kg. Methods Medetomidine (10μgkg -1) was administered IV. Blood was sampled at fixed time points from before drug administration to 48hours post administration. Behavioral, physiological and biochemical data were obtained at predetermined time points from 0minutes to 24hours post administration. An algometer was also used to measure threshold responses to noxious stimuli. Medetomidine concentrations were determined by liquid chromatography-Mass Spectrometry and used for calculation of pharmacokinetic parameters using noncompartmental and compartmental analysis. Results Pharmacokinetic analysis estimated that medetomidine peaked (8.86±3.87ngmL -1) at 6.4±2.7minutes following administration and was last detected at 165±77minutes post administration. Medetomidine had a clearance of 39.6±14.6mLkg -1minute -1 and a volume of distribution of 1854±565mLkg -1. The elimination half-life was 29.1±12.5minutes. Glucose concentration reached a maximum of 176±46mgdL -1 approximately 1hour post administration. Decreased heart rate, respiratory rate, borborygmi, packed cell volume, and total protein concentration were observed following administration. Horses lowered their heads from 107±12 to 20±10cm within 10minutes of drug administration and gradually returned to normal. Horse mobility decreased after drug administration. An increased mechanical threshold was present from 10 to 45minutes and horses were less responsive to sound. Conclusion and clinical relevance Behavioral and physiological effects following intravenous administration positively correlate with pharmacokinetic profiles from plasma medetomidine concentrations. Glucose concentration gradually transiently increased following medetomidine administration. The analgesic effect of the drug appeared to have a very short duration.",
keywords = "Alpha -adrenergic agonist, Horse, Medetomidine, Pharmacodynamics, Pharmacokinetics, Sedation",
author = "Grimsrud, {Kristin N} and Mama, {Khursheed R.} and Eugene Steffey and Stanley, {Scott D}",
year = "2012",
month = "1",
doi = "10.1111/j.1467-2995.2011.00669.x",
language = "English (US)",
volume = "39",
pages = "38--48",
journal = "Veterinary Anaesthesia and Analgesia",
issn = "1467-2987",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of intravenous medetomidine in the horse

AU - Grimsrud, Kristin N

AU - Mama, Khursheed R.

AU - Steffey, Eugene

AU - Stanley, Scott D

PY - 2012/1

Y1 - 2012/1

N2 - Objective To describe the pharmacodynamics and pharmacokinetics following an intravenous (IV) bolus dose of medetomidine in the horse. Study design Prospective experimental trial. Animals Eight, mature healthy horses age 11.7±4.6 (mean±SD) years, weighing 557±54kg. Methods Medetomidine (10μgkg -1) was administered IV. Blood was sampled at fixed time points from before drug administration to 48hours post administration. Behavioral, physiological and biochemical data were obtained at predetermined time points from 0minutes to 24hours post administration. An algometer was also used to measure threshold responses to noxious stimuli. Medetomidine concentrations were determined by liquid chromatography-Mass Spectrometry and used for calculation of pharmacokinetic parameters using noncompartmental and compartmental analysis. Results Pharmacokinetic analysis estimated that medetomidine peaked (8.86±3.87ngmL -1) at 6.4±2.7minutes following administration and was last detected at 165±77minutes post administration. Medetomidine had a clearance of 39.6±14.6mLkg -1minute -1 and a volume of distribution of 1854±565mLkg -1. The elimination half-life was 29.1±12.5minutes. Glucose concentration reached a maximum of 176±46mgdL -1 approximately 1hour post administration. Decreased heart rate, respiratory rate, borborygmi, packed cell volume, and total protein concentration were observed following administration. Horses lowered their heads from 107±12 to 20±10cm within 10minutes of drug administration and gradually returned to normal. Horse mobility decreased after drug administration. An increased mechanical threshold was present from 10 to 45minutes and horses were less responsive to sound. Conclusion and clinical relevance Behavioral and physiological effects following intravenous administration positively correlate with pharmacokinetic profiles from plasma medetomidine concentrations. Glucose concentration gradually transiently increased following medetomidine administration. The analgesic effect of the drug appeared to have a very short duration.

AB - Objective To describe the pharmacodynamics and pharmacokinetics following an intravenous (IV) bolus dose of medetomidine in the horse. Study design Prospective experimental trial. Animals Eight, mature healthy horses age 11.7±4.6 (mean±SD) years, weighing 557±54kg. Methods Medetomidine (10μgkg -1) was administered IV. Blood was sampled at fixed time points from before drug administration to 48hours post administration. Behavioral, physiological and biochemical data were obtained at predetermined time points from 0minutes to 24hours post administration. An algometer was also used to measure threshold responses to noxious stimuli. Medetomidine concentrations were determined by liquid chromatography-Mass Spectrometry and used for calculation of pharmacokinetic parameters using noncompartmental and compartmental analysis. Results Pharmacokinetic analysis estimated that medetomidine peaked (8.86±3.87ngmL -1) at 6.4±2.7minutes following administration and was last detected at 165±77minutes post administration. Medetomidine had a clearance of 39.6±14.6mLkg -1minute -1 and a volume of distribution of 1854±565mLkg -1. The elimination half-life was 29.1±12.5minutes. Glucose concentration reached a maximum of 176±46mgdL -1 approximately 1hour post administration. Decreased heart rate, respiratory rate, borborygmi, packed cell volume, and total protein concentration were observed following administration. Horses lowered their heads from 107±12 to 20±10cm within 10minutes of drug administration and gradually returned to normal. Horse mobility decreased after drug administration. An increased mechanical threshold was present from 10 to 45minutes and horses were less responsive to sound. Conclusion and clinical relevance Behavioral and physiological effects following intravenous administration positively correlate with pharmacokinetic profiles from plasma medetomidine concentrations. Glucose concentration gradually transiently increased following medetomidine administration. The analgesic effect of the drug appeared to have a very short duration.

KW - Alpha -adrenergic agonist

KW - Horse

KW - Medetomidine

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Sedation

UR - http://www.scopus.com/inward/record.url?scp=83455176088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455176088&partnerID=8YFLogxK

U2 - 10.1111/j.1467-2995.2011.00669.x

DO - 10.1111/j.1467-2995.2011.00669.x

M3 - Article

C2 - 22103480

AN - SCOPUS:83455176088

VL - 39

SP - 38

EP - 48

JO - Veterinary Anaesthesia and Analgesia

JF - Veterinary Anaesthesia and Analgesia

SN - 1467-2987

IS - 1

ER -